Leaderboards/Intraperitoneal and Appendiceal Malignancies

Intraperitoneal and Appendiceal Malignancies

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Koen P. Rovers
Radboud University Nijmegen
2
Kristiaan Lenos
Amsterdam Neuroscience
3
Luca Varinelli
Fondazione IRCCS Istituto Nazionale dei Tumori
4
Steven D. Forsythe
Forest Institute
5
Ričards Marcinkevičs
ETH Zurich
6
Amandine Pinto
Centre Hospitalier de Bigorre
7
Mattias Lepsenyi
Malmö University
8
Helena Braet
Ghent University
9
Jean-Marc Classe
Institut de Cancérologie de l'Ouest
10
Sicheng Zhou
Second Affiliated Hospital of Zhejiang University

Rising Stars Papers

1
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial
The Lancet Oncology|2024
62 cit.
2
Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside
Journal of Experimental & Clinical Cancer Research|2024
21 cit.
3
Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6).
Journal of Clinical Oncology|2025
6 cit.
4
A combinatorial culture strategy to develop pseudomyxoma peritonei organoid models
Journal of Surgical Oncology|2024
3 cit.
5
Does concomitant ductal carcinoma in situ influence the prognostic outcome after neoadjuvant therapy in triple-negative invasive ductal carcinoma?
World Journal of Surgical Oncology|2025
2 cit.
6
Differences in treatment response and survival between HER2(2+)/FISH-positive and HER2(3+) breast cancer patients after dual-target neoadjuvant therapy: a matched case-control study
Frontiers in Oncology|2025
1 cit.
7
Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer
iScience|2025
1 cit.
8
External validation of predictive models for diagnosis, management and severity of pediatric appendicitis
Frontiers in Pediatrics|2025
1 cit.
9
149P Treatment landscape for desmoid tumors: Desmoid Tumor Research Foundation Natural History Study
ESMO Open|2024
0 cit.
10
Abstract 4234: Personalized therapeutic screening in patient derived organoids for gastroenteropancreatic neuroendocrine tumors
Cancer Research|2024
0 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Mandy Zournas
St. Antonius Ziekenhuis
2
Gang Chen
Fujian Medical University
3
Nicholas V. Jensen
Cancer Genetics (United States)
4
Sung Sil Park
National Cancer Center
5
Marina Sokolsky‐Papkov
University of North Carolina at Chapel Hill
6
Arend G. J. Aalbers
The Netherlands Cancer Institute
7
Vahan Képénékian
Hospices Civils de Lyon
8
Sanjeev Dayal
Basingstoke and North Hampshire Hospital
9
Kandiah Chandrakumaran
Basingstoke and North Hampshire Hospital
10
Antonio Topete
Universidade de Santiago de Compostela

Emerging Leaders Papers

1
O-Net: A Novel Framework With Deep Fusion of CNN and Transformer for Simultaneous Segmentation and Classification
Frontiers in Neuroscience|2022
49 cit.
2
Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq–guided combination with sapanisertib
Science Advances|2022
44 cit.
3
Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial
Journal of Clinical Oncology|2023
40 cit.
4
<scp>PRAME</scp> is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics
Histopathology|2022
39 cit.
5
Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin
JAMA Surgery|2023
24 cit.
6
A multi-task deep learning framework for perineural invasion recognition in gastric cancer whole slide images
Biomedical Signal Processing and Control|2022
21 cit.
7
Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Frontiers in Genetics|2022
16 cit.
8
2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma
Annals of Surgical Oncology|2023
16 cit.
9
Revisiting gold nanoshells as multifunctional biomedical nanotools
Coordination Chemistry Reviews|2024
16 cit.
10
Influence of Extraperitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases
Annals of Surgical Oncology|2023
13 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Paul H. Sugarbaker
American Institute for Cancer Research
2
David L. Morris
St George Hospital
3
Olivier Gléhen
Hospices Civils de Lyon
4
Ignace H. J. T. de Hingh
Radboud University Nijmegen
5
Marcello Deraco
Fondazione IRCCS Istituto Nazionale dei Tumori
6
Brigitte M. Ronnett
Johns Hopkins Hospital
7
Edward A. Levine
Wake Forest University
8
Patrick Rat
Université Claude Bernard Lyon 1
9
Brendan Moran
Basingstoke and North Hampshire Hospital
10
Robert H. Young
George Washington University Hospital

Current Senior Leaders Papers

1
Peritonectomy Procedures
Annals of Surgery|1995
1.5k cit.
2
Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study
Journal of Clinical Oncology|2004
1.2k cit.
3
Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Journal of Clinical Oncology|2012
1.1k cit.
4
Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study
Journal of Clinical Oncology|2009
993 cit.
5
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
The Lancet Oncology|2021
789 cit.
6
A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia
The American Journal of Surgical Pathology|2015
782 cit.
7
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
Journal of Clinical Oncology|2009
685 cit.
8
Peritoneal carcinomatosis of gastric origin: A population‐based study on incidence, survival and risk factors
International Journal of Cancer|2013
598 cit.
9
The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin
International Journal of Gynecological Pathology|2003
562 cit.
10
Appendiceal Mucinous Neoplasms
The American Journal of Surgical Pathology|2003
553 cit.

Reagents for Intraperitoneal and Appendiceal Malignancies

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 65

PathScan® RP Phospho-ULK1 (Ser638) Sandwich ELISA Kit

#30954$67,830,490
View Evidence →
Cell Signaling TechnologyEvidence 67

ALK (D5F3) Rabbit Monoclonal Antibody

#3633$2,541,756
View Evidence →
Promega

CellTiter-Glo® 3D Cell Viability Assay

#G968B
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 67

IMP3 (D6U2N) Rabbit Monoclonal Antibody

#57145$161,351
View Evidence →
Cell Signaling TechnologyEvidence 65

Bim (C34C5) Rabbit Monoclonal Antibody (Alexa Fluor® 488 Conjugate)

#94805$465
View Evidence →
Cell Signaling TechnologyEvidence 64

Phospho-Met (Tyr1003) Matched Antibody Pair

#72698$1,726
View Evidence →